Clinical Trial Search

Primary: Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir — 5.34; 8.02; 3.74 µM*hr

Primary: Retention — 8; 7 Participants

Primary: Effect of Vitamin D on Angiogenic Factors — 6.7; 5.6; 5.9; 5.5 ratio

Primary: Stroke Health Education Knowledge Questionnaire — 29.07; 28.00 score on a scale

Primary: Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF — 4936; 12484; 11386; 8758 Participants

Primary: Evaluate the Effects of Ketamine on Depressive Symptomatology by Measuring Change in Score on the Montgomery-Asberg Depressive Rating Scale — 28.82; 25.20 units on a scale

Primary: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort — 1.7; 3.0 Percentage of Participants — p=0.282

Primary: Double-Blind Phase: Time to Loss of Therapeutic Response (LTR) — 58; 23 Days — p=0.0186

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 17; 19; 30; 7 Participants

Primary: Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at Week 12 — -0.77; -1.38; -1.36; -1.69 score on a scale — p=0.086

Primary: Number and Prevalence of Patients With Diabetic Retinopathy — 9; 18 Participants — p=0.706

Primary: Total Number of Ranibizumab Injections in Each of the Two Cohorts in a 36 Month Period — 24.4; 27.1 injections

Primary: Change From Baseline in HbA1c to Week 24 — -1.64; -1.59 percentage of HbA1c — p=<.0001

Primary: Subjective Marijuana Effects — 13; 15; 16; 16 units on a scale (0-100mm)

Primary: Percentage of Participants With Complete Hives Response (HSS7=0) — 30.2; 51.2; 42.4; 25.9 Percentage of participants — p=<.05